IQVIA_Rules_Based_Medicine_Logo - rgb

(+01) 512 835 8026

Email us

Type your search term and press "enter."

AdobeStock_189980907

INTERLEUKIN-10 (IL-10) – SIMOA

NEWSROOM

    DATA QUALITY

    Interleukin-10 (IL-10)

    Ultrasensitive Immunoassay

    simoa

    Rules-Based Medicine has developed an ultrasensitive immunoassay to interleukin-10 (IL-10) based on Simoa® bead technology. The ability to accurately quantitate sub-pg/mL levels of IL-10 in human serum and plasma is a valuable clinical research tool for pharmacodynamic analysis in oncology, autoimmune, and chronic infectious diseases.

    IL-10 is a type II cytokine with anti-inflammatory properties, IL-10 is secreted by macrophages, dendritic cells, B cells, and T cells, and modulates their functions to minimize tissue damage during acute phases of immune responses. IL-10 is a homodimer that signals through a functional receptor complex composed of two IL-10 receptor-1 proteins and two IL-10 receptor-2 proteins via STAT3, JAK1, and Tyk2. IL-10 inhibits the secretion of pro-inflammatory cytokines such as IL-1β, IL-12, IFNγ, and TNFα from TLR-activated myeloid cells after exposure to bacterial products. IL-10 promotes B cell survival, proliferation and upregulates antibody production. It decreases Th1 cytokines, MHC class II, and co-stimulatory molecules expression on macrophages.

    The pleiotropic role of IL-10 in immunoregulation and inflammation has been implicated in many pathogenic states including autoimmune diseases and cancer. Risk of prostate cancer has been associated with SNPs in IL-10. SNPs in the promoter region have been associated with risk of lung cancer among Asians and Caucasians. IL-10 levels are significantly increased in serum from patients with tuberculosis, and during viral infections, IL-10 triggers and modulates antiviral T cell responses. Although recombinant human IL-10 has been tested for Crohn’s disease, rheumatoid arthritis, psoriasis, hepatitis C, and HIV, the transition from testing to clinical application has been hindered by dosing and administration difficulties. In patients with advanced renal cell cancer, pegylated IL-10 has been shown to have antitumor activity.

     

    Swiss-Prot Accession Number: P22301
    Simoa™ Services
    Biomarker LLOQ*
    (Serum and Plasma)    		 LLOQ*
    (Undiluted Samples)    		 Volume Required
    Serum or plasma Other fluids**
    Interleukin-10 (IL-10) 0.037 pg/mL 0.0092 pg/mL 100 µL 150 µL

    * Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.

    ** Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.

    All assay services are performed in our CLIA-certified laboratory.
    Intended for Research Use Only.